<DOC>
	<DOCNO>NCT00919061</DOCNO>
	<brief_summary>The purpose study test investigational combination drug bile duct gallbladder cancer . Gemcitabine cisplatin two form chemotherapy commonly use combination treat bile duct gallbladder cancer . We look improve treatment result . We attempt add sorafenib ( type monoclonal antibody ) treatment plan . Sorafenib act attach block specific target cell . These target may help cancer cell grow divide . This study help answer question whether sorafenib helpful drug patient bile duct gallbladder cancer give gemcitabine cisplatin . This study phase 2 study . The purpose phase 2 study find effect , good and/or bad , sorafenib combination gemcitabine cisplatin advance bile duct gallbladder cancer .</brief_summary>
	<brief_title>Gemcitabine Cisplatin Plus Sorafenib Patients With Advanced Biliary Tract Carcinomas Naive Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically / cytologically verify , nonresectable , recurrent , metastatic biliary tract carcinoma include intrahepatic cholangiocarcinoma , extrahepatic cholangiocarcinoma gallbladder carcinoma . Combined cholangiocarcinoma hepatocellular carcinoma allowed.Patients must unidimensionally measurable disease xray , CT scan , MRI scan physical examination . KPS ≥ 80 % Age ≥ 18 year Adequate bone marrow function define : Hb ≥ 8 g/dl , ANC ≥ 1.5 K/mcL , Platelets ≥ 100 K/mcL Adequate renal function define Serum creatinine &lt; 2.0 mg/dl calculate creatinine clearance ≥ 60 ml/min use formula : CockcroftGault formula : CockcroftGault Formula MALES CrCl = ( 140 age [ year ] ) ( body wt [ kg ] ) ( 72 ) ( serum creatinine [ mg/dL ] ) CockcroftGault Formula FEMALES CrCl = 0.85 x male value If calculate creatinine clearance within range use formula , measure level 24hour urine collection may use calculate creatinine clearance . Adequate hepatic function define total bilirubin ≤ 2 mg/dl , ALT/AST/ ≤ 3 x ULN ( ≤ 5 liver metastasis ) . Patients biliary obstruction join bilirubin corrects require limit adequate biliary drainage . PT/INR ≤ 1.7 PTT ≤ 1.5 x ULN , unless patient receive anticoagulation therapy agent warfarin heparin Patients receive prior local therapy , i.e . embolization , radiation therapy , etc . ( except chemoembolization ) eligible provide measurable disease fall outside treatment field within field show increase ≥20 % size . Prior local therapy must complete least 4 week prior baseline scan Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients encourage continue barrier method contraception two year longer treatment . Ability understand willingness sign write informed consent document Any previous chemotherapy , biologic therapy , investigational agent , except 5FU gemcitabine give adjuvant therapy single agent and/or radiosensitizing agent . Patient must complete adjuvant therapy less six month prior accrual . Patients previous significant allergic hypersensitivity gemcitabine exclude . Evidence another active cancer may influence patient outcome determine Principal Investigator , except nonmelanoma skin carcinoma , melanoma insitu , insitu carcinoma cervix curatively treat , treat superficial bladder cancer , adenocarcinoma prostate surgically treat posttreatment PSA nondetectable . Known brain metastasis History primary central nervous system tumor brain metastasis , and/or seizure well control standard medical therapy . Uncontrolled intercurrent illness include , limited psychiatric illness/social situation would limit compliance study requirement . Known HIV positive patient Blood Pressure &gt; 150/100 mm Hg Significant cardiovascular disease include congestive heart failure ( New York Heart Association Class II high ) active angina pectoris . History myocardial infarction within 6 month . History stroke transient ischemic attack within 6 month . Clinically significant peripheral vascular disease . Evidence bleed diathesis coagulopathy . Major surgical procedure , open biopsy , significant traumatic injury within 4 week . Uncontrolled infection . Known suspected allergy sorafenib agent give course trial . Pregnant ( positive pregnancy test ) Breastfeeding discontinue mother treated clinical trial . Serious nonhealing wound , ulcer , bone fracture Use St. John 's Wort rifampin ( rifampicin ) Any condition impair patient 's ability swallow whole pill Any malabsorption problem</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>GALL BLADDER</keyword>
	<keyword>BILE DUCTS</keyword>
	<keyword>BAY 43-9006</keyword>
	<keyword>SORAFENIB</keyword>
	<keyword>CISPLATIN</keyword>
	<keyword>GEMCITABINE</keyword>
	<keyword>09-029</keyword>
</DOC>